Treatment patterns of melanoma by BRAF mutation status in the USA from 2011 to 2017: a retrospective cohort study.

IF 1 Q4 ONCOLOGY

Melanoma Management Pub Date : 2019-11-05 DOI:10.2217/mmt-2019-0013

Shweta Shah, Leon Raskin, David Cohan, Omid Hamid, Morganna L Freeman

{"title":"Treatment patterns of melanoma by BRAF mutation status in the USA from 2011 to 2017: a retrospective cohort study.","authors":"Shweta Shah, Leon Raskin, David Cohan, Omid Hamid, Morganna L Freeman","doi":"10.2217/mmt-2019-0013","DOIUrl":null,"url":null,"abstract":"Aim: To describe treatment changes from 2011 to 2017 and demographic/clinical characteristics of patients with advanced melanoma who received systemic therapy by BRAF status.Patients & methods: Treatment patterns were evaluated in adults from the Oncology Services Comprehensive Electronic Records database who received antimelanoma systemic therapy.Results: Checkpoint inhibitors were prevailingly prescribed (66%); usage increased from 2011 (21%) to 2017 (84%). BRAF/MEK inhibitors were the second most common (21%); usage increased from 2011 (6%) to 2012 (18%) and stabilized until 2017 (22%). BRAF/MEK inhibitors (65%) and checkpoint inhibitors (57%) were predominantly used for BRAFMut melanoma.Conclusion: Overall, checkpoint inhibitors have supplanted other therapies for advanced melanoma. Treatment shifts have occurred for BRAFMut melanoma, notably increased use of checkpoint inhibitors and BRAF/MEK combinations compared with monotherapies.","PeriodicalId":44562,"journal":{"name":"Melanoma Management","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2019-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/mmt-2019-0013","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Melanoma Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/mmt-2019-0013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 2

Abstract

Aim: To describe treatment changes from 2011 to 2017 and demographic/clinical characteristics of patients with advanced melanoma who received systemic therapy by BRAF status.

Patients & methods: Treatment patterns were evaluated in adults from the Oncology Services Comprehensive Electronic Records database who received antimelanoma systemic therapy.

Results: Checkpoint inhibitors were prevailingly prescribed (66%); usage increased from 2011 (21%) to 2017 (84%). BRAF/MEK inhibitors were the second most common (21%); usage increased from 2011 (6%) to 2012 (18%) and stabilized until 2017 (22%). BRAF/MEK inhibitors (65%) and checkpoint inhibitors (57%) were predominantly used for BRAF^Mut melanoma.

Conclusion: Overall, checkpoint inhibitors have supplanted other therapies for advanced melanoma. Treatment shifts have occurred for BRAF^Mut melanoma, notably increased use of checkpoint inhibitors and BRAF/MEK combinations compared with monotherapies.

Abstract Image

查看原文本刊更多论文

2011年至2017年美国BRAF突变状态下黑色素瘤的治疗模式：一项回顾性队列研究。

目的：描述2011年至2017年的治疗变化以及接受BRAF状态系统治疗的晚期黑色素瘤患者的人口统计学/临床特征。患者和方法：从肿瘤服务综合电子记录数据库中评估接受抗黑色素瘤系统治疗的成年人的治疗模式。结果：检查点抑制剂处方占66%；使用量从2011年（21%）增加到2017年（84%）。BRAF/MEK抑制剂是第二常见的（21%）；使用量从2011年（6%）增加到2012年（18%），并稳定到2017年（22%）。BRAF/MEK抑制剂（65%）和检查点抑制剂（57%）主要用于BRAFMut黑色素瘤。结论：总的来说，检查点抑制剂已经取代了其他治疗晚期黑色素瘤的方法。BRAFMut黑色素瘤的治疗发生了变化，与单一疗法相比，检查点抑制剂和BRAF/MEK组合的使用显著增加。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Melanoma Management ONCOLOGY-

CiteScore

5.10

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing. Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. Key topics covered include: Risk factors, prevention and sun safety education Diagnosis, staging and grading Surgical excision of melanoma lesions Sentinel lymph node biopsy Biological therapies, including immunotherapy and vaccination Novel chemotherapy options Treatment of metastasis Prevention of recurrence Patient care and quality of life.